Elicio Therapeutics (ELTX) Common Equity (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Common Equity data on file, last reported at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 116.14% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 million (down 116.14% YoY), and the FY2025 full-year result was $1.6 million, up 114.46% from the prior year.
• Common Equity for Q1 2026 stood at -$1.4 million, down from $1.6 million in the prior quarter.
• Across five years, Common Equity topped out at $23.6 million in Q2 2023 and bottomed at -$109.9 million in Q1 2023.
• The 5-year median for Common Equity is -$1.4 million (2026), against an average of -$26.0 million.
• The widest annual swing landed in 2022, when Common Equity plunged 248.34%; it then surged 211.02% in 2025.
• A 5-year view of Common Equity shows it stood at -$102.1 million in 2022, then surged by 111.13% to $11.4 million in 2023, then tumbled by 199.46% to -$11.3 million in 2024, then jumped by 114.46% to $1.6 million in 2025, then tumbled by 187.84% to -$1.4 million in 2026.
• The last three Common Equity figures came in at -$1.4 million (Q1 2026), $1.6 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.

Peer Comparison